

Republic of Moldova

| High MDR-TB burden |

Tuberculosis profile

Population 2013

3.5 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.48 (0.45–0.5)	14 (13–14)
Mortality (HIV+TB only)	0.081 (0.063–0.1)	2.3 (1.8–2.9)
Prevalence (includes HIV+TB)	7.9 (4–13)	226 (113–375)
Incidence (includes HIV+TB)	5.5 (5–6.3)	159 (142–180)
Incidence (HIV+TB only)	0.34 (0.3–0.4)	9.8 (8.5–11)
Case detection, all forms (%)	81 (71–91)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	24 (21–26)	62 (59–65)
MDR-TB cases among notified pulmonary TB cases	770 (700–850)	880 (840–930)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	1 865	542
Pulmonary, clinically diagnosed	1 403	309
Extrapulmonary	336	30

Total new and relapse	4 485
Previously treated, excluding relapses	566
Total cases notified	5 051

Among 4 485 new and relapse cases:

134 (3%) cases aged under 15 years; male:female ratio: 2.6

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	1 610 (86%)	996 (69%)	2 620
Laboratory-confirmed RR-/MDR-TB cases			1 054
Patients started on MDR-TB treatment			931

TB/HIV 2013	Number	(%)
TB patients with known HIV status	4 085	(81)
HIV-positive TB patients	250	(6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	165	(66)
HIV-positive people screened for TB	3 332	
HIV-positive people provided with IPT		

Treatment success rate	(%)
New and relapse cases registered in 2012	76
Previously treated cases, excluding relapse, registered in 2012	39
HIV-positive TB cases, all types, registered in 2012	47
RR-/MDR-TB cases started on second-line treatment in 2011	54
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	1.6
Culture (per 5 million population)	5.7
Drug susceptibility testing (per 5 million population)	5.7
Sites performing Xpert MTB/RIF	28
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	33
% Funded domestically	12%
% Funded internationally	21%
% Unfunded	67%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded